SCHEDULE: FMR LLC Discloses 7.1% Stake in Eikon Therapeutics

FMR LLC and Abigail P. Johnson have jointly reported beneficial ownership of 7.1% of Eikon Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Eikon Therapeutics Inc. common stock.
• As of March 31, 2026, the total number of shares beneficially owned is 3,836,830.
• This represents 7.1% of the total class of securities.
• FMR LLC, organized in Delaware, is classified as a holding company (HC).
• Abigail P. Johnson, a U.S. citizen, is classified as an insider (IN) in relation to FMR LLC.
• The filing indicates that FMR LLC has sole voting power and sole dispositive power over these shares.
• FIAM LLC and Fidelity Management Trust Company are identified as entities that beneficially own 5% or greater of the security class, with FIAM LLC classified as an Investment Adviser (IA) and Fidelity Management Trust Company as a Bank (BK).
• A shareholder voting agreement among members of the Johnson family may lead to them being considered a controlling group with respect to FMR LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates sustained or increased confidence from a major institutional investor, but lacks operational or financial performance data.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in Eikon Therapeutics.
• Clear reporting of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or operational updates, limiting the assessment of the company's health.

Risks

• The filing does not explicitly mention any risks associated with Eikon Therapeutics Inc.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant filings like Schedule 13Gs from major institutional investors such as FMR LLC often signal a level of conviction in a company's long-term prospects, particularly in the biotechnology and therapeutics sector where substantial capital and long development cycles are common.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially leading to greater market stability or analyst coverage.
• Management: The filing provides transparency regarding significant ownership, which is a standard disclosure requirement.

Next Steps

• Continued monitoring of FMR LLC's ownership stake in Eikon Therapeutics Inc.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not contain financial performance data or strategic updates that would warrant a buy or sell recommendation. It confirms a significant institutional holding, suggesting stability but not necessarily immediate upside.

Keywords

Eikon Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Fidelity, FIAM LLC, Fidelity Management Trust Company